Diane M. Joseph

Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.

J. Hochman, J. Tcheng, N. Kleiman, 2002, Journal of the American College of Cardiology.

Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention.

W. Cantor, J. Tcheng, M. Madan, 2000, American heart journal.

A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction.

R. Roberts, C. O'connor, T. Henry, 2011, American heart journal.

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study

K. Mahaffey, R. Becker, R. Harrington, 2009, The Lancet.

Genome-wide association study of perioperative myocardial infarction after coronary artery bypass surgery

Yi-Ju Li, J. Alexander, M. Newman, 2015, BMJ Open.

The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics.

Robert M Califf, R. Califf, M. Mack, 2005, American heart journal.

Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease.

R. Califf, E. Topol, P. Armstrong, 2000, Circulation.